Data from Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy

Le résumé fourni par la source

Abstract Purpose: Advances in cancer therapy have improved survival but increased the risk of treatment-related cardiotoxicity, which remains difficult to detect early with existing biomarkers. [18F]F-AraG is a positron emission tomography (PET) tracer that targets cells with active mitochondrial biogenesis, including cardiomyocytes and activated T cells, and may enable concurrent assessment of cardiac involvement and therapy-associated immune activity. This study evaluated whether [18F]F-AraG PET can serve as an early imaging biomarker of cardiac effects across different cancer therapies. Experimental Design: Twenty-six healthy subjects underwent [18F]F-AraG PET to establish baseline myocardial uptake. Seven patients with stage III melanoma and 10 with advanced non–small cell lung cancer were imaged before and after immunotherapy. Myocardial uptake (SUVmax, SUVmean, and SUVtotal) was quantified in the left ventricle (LV) and right ventricle (RV), with LV regional uptake analyzed using a 17-segment model. Myocardial uptake was examined in relation to abnormal cardiac status in a subset of patients with available electrocardiogram (ECG) data. Associations between cardiac uptake, mitochondrial content, and PGC1α expression were evaluated. Results: Healthy myocardium demonstrated consistent and spatially uniform [18F]F-AraG uptake across age and sex, with higher uptake in the LV than in the RV. Conventional therapy was associated with increased global myocardial uptake, whereas immunotherapy was associated with additional heterogeneous and focal myocardial uptake. Altered myocardial uptake patterns were observed in patients with ECG abnormalities. Conclusions: [18F]F-AraG PET detects therapy-associated changes in myocardial tracer uptake following cancer treatment. These findings support its potential utility as a noninvasive imaging approach for the early evaluation of cardiac effects in patients receiving cancer therapies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.